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Abstract
Background: The efficacy of telemedicine in the management of patients with chronic heart failure and left ventricular
ejection fraction 40% is poorly understood. The aim of our analysis was to evaluate the efficacy of a telemedicine-
based intervention specifically in these patients, as compared to standard of care alone.
Methods: The Insuficiència Cardiaca Optimitzacio Remota (iCOR) study was a single centre, randomised, controlled
trial, designed to evaluate a telemedicine intervention added to an existing hospital/primary care multidisciplinary,
integrated programme for chronic heart failure patients. 178 participants were randomised to telemedicine or usual
care, and were followed for six months. For the present sub-analysis, only iCOR participants (n¼ 116) with left
ventricular ejection fraction 40% were included. The primary study endpoint was the incidence of an acute non-
fatal heart failure event, defined as a new episode of worsening of symptoms and signs consistent with acute heart failure
requiring intravenous diuretic therapy. The healthcare-related costs in each study group were also evaluated.
Results: The incidence of the first occurrence of the primary endpoint was significantly lower in the telemedicine arm
(22% vs 56%, p<0.001), with a hazard ratio of 0.33 comparing to the usual care arm (95% confidence interval 0.17–0.64).
Telemedicine was also associated with lower mean overall chronic heart failure care-related costs compared to usual
care (8163e vs 4993e, p¼0.001). The results were consistent in both left ventricular ejection fraction of 40–49% and left
ventricular ejection fraction 50% patients.
Conclusions: Our results suggest that telemedicine is a promising strategy for the management of chronic heart failure
patients with left ventricular ejection fraction 40%. These findings should be replicated in larger cohorts.
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Introduction
Chronic heart failure (CHF) is a growing public health
issue.1–3 In recent decades, population ageing and
improvements in the treatment of most cardiovascular
conditions have resulted in an increasing incidence and
prevalence of CHF in most Western countries.1–3 The
epidemiological importance, the burden caused by this
health issue, and its high lethality,4 highlight the need
for improved management approaches.
Approximately half of the patients with CHF have a
left ventricular ejection fraction (LVEF) <40% – the so
called ‘heart failure with reduced LVEF’ (HFrEF).5,6
The pathophysiology and clinical characteristics of
HFrEF are currently well established, and research
efforts in recent decades have resulted in the develop-
ment of a number of evidence-based therapies available
for the treatment of these patients.7–10 On the other
hand, the pathophysiology and therapeutic options
for the remaining half of patients with CHF and
LVEF 40% are not so well established,11–14 and fur-
ther research is warranted in this patient population.
Telemedicine has become one of the key areas of
development and research in CHF management in
the last decade.15–20 Although the effectiveness of tele-
medicine in CHF has been controversial, recent pooled
data suggest an overall beneficial effect in patients at
higher risk of events.18 Specifically, both structured
telephone support and non-invasive telemonitoring
showed promise in reducing mortality, heart failure
(HF) hospitalizations and improving quality of life.
However, most of the studies published so far included
mostly patients with HFrEF, therefore, the efficacy of
telemedicine in the management specifically of patients
with CHF and LVEF 40% is poorly understood.18,21
In the recent Insuficiència Cardiaca Optimitzacio
Remota (iCOR) study,17 a randomised, single-centre,
controlled trial evaluating the efficacy of telemedicine
in a cohort of CHF patients including both LVEF
<40% and 40%, telemonitoring and teleinterventions
based on bio-measure analysis, and videoconferences
with patients or caregivers showed benefits in terms
of non-fatal events and healthcare cost reduction.17
The aim of the present subanalysis is to evaluate the
efficacy of the intervention specifically in the subgroup
of participants with LVEF 40%, including HF
patients with both mid-range ejection fraction
(HFmrEF, defined as a LVEF 40–49%)5 as well as
patients with preserved ejection fraction (HFpEF,
LVEF 50%).5
Materials and methods
Study design, context and population
Details on the methods of the iCOR trial have been
described before.17 Briefly, this was a single centre,
randomised, controlled, open-label trial, designed to
evaluate the efficacy of adding telemedicine to an exist-
ing hospital/primary care integrated chronic manage-
ment programme for patients with CHF.17 The study
was carried out in a previously existing, specialised,
multidisciplinary, nurse-based, hospital/primary care
integrated CHF management programme.22
The study recruitment period took place between
December 2010–October 2012, and patients were
recruited after discharge for an acute HF decompensa-
tion requiring hospital admission in our centre.
Inclusion criteria for the iCOR trial were: age of
18 years or older; presence of a diagnosis of CHF,
defined by the presence of 3 months of typical signs
and symptoms, plus evidence of underlying structural
heart disease or current hospital admission for acute
decompensated HF needing intravenous diuretics;
and being alive at hospital discharge. Exclusion criteria
were being institutionalised, cognitive impairment
without a caregiver, end-of-life care, planned cardiac
invasive procedures, or planned haemodialysis. All
iCOR participants provided written informed consent,
the study protocol was approved by the institutional
review board of the Hospital del Mar Research
Institute (IMIM), and was registered on the website
www.ClinicalTrials.gov (NCT01495078).17
For the present analysis, only iCOR participants
with a baseline LVEF 40% were included. No further
inclusion or exclusion criteria were implemented.
Baseline data collection
Baseline information including demographic character-
istics, functional evaluation, medical history, physical
examination, laboratory test results and other relevant
clinical data was collected from each patient’s medical
history. All participants underwent a complete
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psychosocial, self-efficacy and health-related quality of
life evaluation.
Study endpoints, follow-up and event ascertainment
The primary study endpoint was the development of an
acute non-fatal HF event, defined as a new episode of
worsening of symptoms and signs consistent with acute
HF requiring intravenous diuretic therapy. This includ-
ed both HF decompensations leading to a hospitaliza-
tion, as well as decompensations managed in the
daycare clinic.
As secondary study endpoints, the following events
were assessed: incident HF hospitalizations, cardiovas-
cular hospitalizations, non-cardiovascular hospitaliza-
tions, all-cause hospitalizations, all-cause death,
cardiovascular death; as well as the combined end-
points of all-cause death or non-fatal HF events and
all-cause death or HF hospitalization.
Additionally, we evaluated the healthcare-related
costs in each study group, using actual cost data
derived from the care of these patients (rather than
estimations). Details on the cost calculations used in
the iCOR study have been published before.17
All participants were followed for a period of six
months. Information on the occurrence of the study
endpoints was obtained by study investigators from
the hospital and primary care electronic medical
records and/or by direct interview of the patients.
Study interventions
The acute phase in-hospital management as well as the
acute and chronic pharmacological management of the
patients included in the iCOR trial were consistent
across patients, and followed the protocols of the
local CHF unit, which were based on the standards
and recommendations published by the relevant scien-
tific societies.5,6 Also, all patients were evaluated in an
early, post-discharge visit occurring no later than seven
days after hospital discharge.
With regards to the chronic, post-discharge follow-
up of the patients included in the iCOR trial,
participants were randomised to either ‘usual care’ or
‘telemedicine’. ‘Usual care’ consisted of several pre-
specified, on-site, face-to-face, structured follow-up
encounters, and patients were instructed to self-
monitor their bio-measures on a daily basis and contact
the nurses in the event of any abnormality (e.g. weight
gain, incipient decompensation signs). In the case of a
mild decompensation, nurses performed diuretic dose
adjustments, either themselves or with the support of
CHF physician specialist.
On the other hand, ‘telemedicine’ consisted of the
same number of pre-specified, structured follow-up
encounters, but these were performed remotely rather
than on site, using videoconference or audioconference.
In these remote visits, the interventions were identical
to those conducted in the usual care arm, including
health education and pharmacological up-titration
interventions (‘teleintervention’). Patients were
instructed to self-monitor their bio-measures on a
daily basis and register this information together with
any HF signs and symptoms in an user-friendly soft-
ware, which transferred this data immediately to the
HF unit (‘telemonitoring’). Automated algorithms
were created to allow for the automatic identification
of decompensations on their very early stages using this
information, and nurses reviewed this data together
with any alerts generated by the system on a daily
basis. In the event of an alert, nurses actively contacted
the patient, and medication adjustments were per-
formed, either by themselves or with the support of
CHF physician specialist, following the same protocols
as those used in the usual care arm.
Statistical analyses
Demographic and clinical baseline characteristics were
summarised overall and by study arm. For continuous
variables, the mean and standard deviation were calcu-
lated. For categorical variables, the number and %
were reported. Comparisons between study arms were
performed using Student’s t and v2 tests for continuous
and categorical variables, respectively.
The incidence proportion of the first occurrence of
each of the study endpoints was calculated for each
study arm, and these compared using v2 tests.
Additionally, Kaplan-Meier cumulative survivor func-
tion curves were used to describe the event-free survival
experience of the two study groups specifically for the
primary study endpoint, and log-rank tests were used
to compare the curves. The associations between tele-
medicine (compared to usual care) and each of the
study endpoints were also evaluated using Cox
proportional-hazards regression models.
Unitary direct hospital costs were compared
between treatment groups using non-parametric tests
(Kolmogorov-Smirnov test for two indepen-
dent samples).
All analyses were conducted both for the overall
study population (i.e. iCOR participants with LVEF
40%), as well as stratifying by LVEF subgroup
(HFmrEF and HFpEF). Formal interaction tests for
the interaction term study armLVEF subgroup were
also conducted for each of the study endpoints.
All significance tests and confidence intervals (CIs)
were constructed with a type I error (alpha) level of
5%. A p value of 0.05 was used as the threshold for
statistical significance. All analyses were conducted
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The original iCOR study population included 178 par-
ticipants, 97 of which were randomised to usual care
and 81 to telemedicine.17 For the present sub-analysis,
62 patients with LVEF <40% were excluded, yielding a
total study population of 116 participants, 66 of which
had been randomised to the usual care arm, and 50 to
the telemedicine arm (Figure 1). With regards to LVEF
subgroups, 27 participants had HFmrEF, and 89
had HFpEF.
Baseline characteristics of the study participants
The baseline characteristics of the participants included
in the present analysis are summarised in Table 1.
Overall, median age was 77 years, 47% were women,
and 28% were considered frail patients. Mean LVEF
was 58%, and almost half of the patients had a New
York Heart Association (NYHA) functional class of
III or IV. The most frequent measured comorbidity
was hypertension (91%), followed by iron deficiency
(64%). The prevalence of anaemia, chronic kidney
disease, diabetes mellitus and atrial fibrillation was
also very high. In terms of pharmacological manage-
ment, 98% participants were using diuretics, 80% were
treated with betablockers, and 58% with angiotensin-
converting-enzyme inhibitors (ACEIs) or angiotensin
receptor blockers (ARBs).
After randomization, both study arms (usual care,
telemedicine) were well balanced in terms of their base-
line characteristics.
Primary study endpoint
A total of 79 events of the primary endpoint happened
during follow-up, 18 in the telemedicine arm (11 first
events) and 61 in the usual 23 care arm (37 first events)
(Table 2). The incidence proportion of the first occur-
rence of the primary endpoint was significantly lower in
the telemedicine arm than in the usual care arm (22%
vs 56%, p< 0.001), with a hazard ratio (HR) of 0.33
comparing the telemedicine arm, to the usual care arm
(95% CI 0.17–0.64). The Kaplan-Meier cumulative
incidence curves of the primary study endpoint for
both study arms are presented in Figure 2(a) (p value
of the Log Rank test <0.001).
Secondary study endpoints
There were statistically significant lower risks of HF-
related, cardiovascular-related, and all-cause
Figure 1. Flowchart of the study participants.
iCOR: Insuficiència Cardiaca Optimitzacio Remota; LVEF: left ventricular ejection fraction; N: number.
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hospitalizations comparing telemedicine to usual care
(Table 2). On the other hand, hospitalization from non-
cardiovascular causes was similar in the two arms.
With regards to fatal endpoints, the number of events
was small in both arms, yielding wide 95% CIs that
included the null value. Nevertheless, the incidence of
all-cause death in the telemedicine arm (6%) was half
that in the usual care arm (12%). Finally, telemedicine
compared to usual care was also associated with a sta-
tistically significant lower risk of each of the combined
study endpoints.
Cost analyses
In terms of healthcare costs, telemedicine was associat-
ed with significantly lower mean overall HF







Age, years 77 (10) 78 (10) 77 (11)
Women 55 (47) 32 (49) 23 (46)
BMI, kg/m2 28 (6) 28 (5) 28 (6)
Blood pressure, mm Hg
Systolic 124 (22) 126 (19) 122 (25)
Diastolic 69 (14) 68 (14) 70 (15)
Heart rate, bpm 73 (13) 74 (13) 71 (12)
NYHA functional class
I–II 60 (52) 36 (55) 24 (48)
III–IV 56 (48) 30 (46) 26(52)
LVEF, % 58 (10) 59 (11) 56 (10)
Ischaemic cause of HF 37 (32) 21 (32) 16 (32)
Comorbidities
Hypertension 106 (91) 61 (92) 45 (90)
Atrial fibrillation 57 (49) 32 (49) 25 (50)
Diabetes mellitus 58 (50) 34 (52) 24 (48)
CKDa 71 (61) 41 (62) 30 (60)
COPD 30 (26) 14 (21) 16 (32)
Iron deficiencyb 74 (64) 42 (64) 42 (64)
Anaemia 65 (56) 38 (58) 27 (54)
Psychosocial evaluation
Self-efficacy, points 21 (10) 20 (10) 21 (10)
Frailty 33 (28) 17 (26) 16 (32)
Educational level
Illiterate 6 (5) 3 (5) 3 (6)
Elementary education 81 (70) 46 (70) 35 (70)
Middle school or higher 29 (25) 17 (26) 12 (24)
Treatment
ACEI or ARBs 67 (58) 38 (58) 29 (58)
Beta-blockers 93 (80) 55 (83) 38 (76)
Aldosterone antagonist 9 (8) 5 (8) 4 (8)
Digoxin 23 (20) 14 (21) 9 (18)
Diuretics 114 (98) 64 (94) 50 (100)
Hydralazine-nitrate combination 32 (28) 17 (25) 15 (39)
Antiplatelet/anticoagulant therapy 101 (87) 55 (83) 46 (92)
Laboratory measurements
Haemoglobin, g/dl 12.1 (2.8) 11.9 (3) 12.4 (2.4)
eGFR, ml/min/1.73 m2 58 (26) 56 (25) 60 (27)
NT-proBNP, pg/mlc 1316 (678–2792) 1757 (718–3451) 1056 (649–2414)
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; CKD: chronic kidney disease;
COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; HF: heart failure; LVEF: left ventricular
ejection fraction; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; NYHA: New York Heart Association.
Data presented as number (%) or mean (standard deviation), unless specified otherwise.
aDefined as eGFR<60 ml/min/1.73 m2.
bDefined as ferritin<100 n/ml or % transferrin saturation (TSAT)<20%
cPresented as median and interquartile range.
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care-related costs compared to usual care (8163e vs
4993e, p¼0.001). Regarding individual cost compo-
nents, compared to telemedicine, usual care was asso-
ciated with higher costs related to hospitalization
(6064e vs 2750e, p¼0.006), and slightly higher costs
related to diagnostic procedures (1386e vs 576e,
p¼0.001). On the other hand, telemedicine was associ-
ated with slightly higher costs related to ambulatory
care (712e vs 1667e, p¼0.001).
Subgroup analyses: HFmrEF and HFpEF
The analyses for the primary and secondary study end-
points were also conducted further stratifying by LVEF
40% subtype (HFmrEF, HFpEF). The results of
these analyses were consistent with those from the
overall analyses, with similar benefits of telemedicine
in patients with HFpEF and with HFmrEF (Table 2
and Figure 2(b)). Consistent with this, the p values of
all tests evaluating the interaction between study arms
and LVEF subgroups were not statistically significant
for any of the study endpoints.
Discussion
In this sub-analysis of a randomised controlled trial
restricted to patients with CHF and LVEF 40%, tele-
medicine, as compared to usual care, was associated
with a lower risk of non-fatal acute HF events, and a
lower risk of hospitalization at six months of follow-
up. These results were robust, and were consistent
across LVEF subtypes (HFpEF, HFmrEF).
Telemedicine may thus provide an opportunity to
improve the outcomes of individuals with CHF and
LVEF 40%, a patient population in whom most
pharmacological interventions have shown limited ben-
efit.21 To our knowledge, this is the first study to spe-
cifically assess the potential benefits of telemedicine
interventions in patients with CHF and LVEF
40%,18,21 and has important implications for the
management of these patients.
Potential mechanisms for the observed associations
follow. First, despite the implementation in our area of
a multidisciplinary, comprehensive, specialised, transi-
tional chronic care programme including early post-
discharge assessments, pre-specified visits and close,
structured follow-up,22 it must be noted that between
usual care visits, the patient is responsible for recording
their HF signs, symptoms and bio-measures; and more
important, for interpreting them and evaluating their
implications (the nurse/physician only become aware of
abnormalities between visits if the patient considers
them important enough to contact the HF team).
Although in our programme, CHF patients are system-
atically empowered with health education and detailed
instructions on how to proceed in the event of a decom-
pensation, unfortunately sometimes they fail to imple-
ment these recommendations, leading to severe
decompensations requiring intravenous drugs and/or
urgent hospitalization. In this context, telemedicine,
via remote daily monitoring of the patient by the HF






















Non-fatal HF events 61 37 56 18 11 22 <0.001 0.33 (0.17–0.64) 0.809
Secondary study endpoints
HF hospitalization 29 23 35 10 7 14 0.011 0.38 (0.16–0.90) 0.933
CV hospitalization 37 27 41 13 9 18 0.009 0.40 (0.19–0.86) 0.305
Non-CV hospitalization 12 9 14 7 6 12 0.796 1.01 (0.35–2.88) 0.248
All-cause hospitalization 51 33 50 21 14 28 0.017 0.52 (0.28–0.98) 0.218
All-cause death 8 8 12 3 3 6 0.267 0.65 (0.16–2.61) 0.890
CV death 6 6 9 2 2 4 0.286 0.66 (0.12–3.58) 0.566
All cause death or
non-fatal HF event
37 37 56 11 11 22 <0.001 0.33 (0.17–0.64) 0.809
All cause death of
HF hospitalization
24 24 36 7 7 14 0.007 0.36 (0.16–0.85) 0.933
CI: confidence interval; CV: cardiovascular; HF: heart failure; HR: hazard ratio; No.: number.
Data are presented as number, incidence proportion (in %), and as hazard ratios (and 95% CIs) from the Cox Proportional Hazards regression models,
respectively.
aComparing the incidence proportion of each endpoint in the usual care arm and the telemedicine arm.
bValue of p for the interaction interaction term study arm*LVEF subgroup, for each study endpoint.
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team allows for reminding the patient to record this
information on a daily basis, as well as for the system-
atic evaluation of this data using automated algo-
rithms, and for the early detection of mild HF
decompensations. This allows treatment adjustments
on a timely manner, preventing the further worsening
of the patient and the need for intravenous drugs.
Second, acute decompensations are frequent in patients
with CHF and LVEF 40%.21 This was also the case
in our study population, despite the multidisciplinary
Figure 2. Cumulative incidence of the primary study endpoint, by study arm (panel (a)), and further stratified by left ventricular
ejection fraction (LVEF) subtype (panel (b)).
HF: heart failure; HFmrEF: heart failure with mid-range ejection fraction; HFpEF: heart failure with preserved ejection fraction.
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CHF programme to which all patients were exposed.
The very high rates of events observed likely explain
the fact that we were able to find statistically significant
differences between the two study arms in spite of the
short follow-up used and the small study popula-
tion included.
Our study has important clinical implications. As of
now, most trials involving pharmacological interven-
tions have failed to show benefit in patients with
CHF and LVEF 40%.11–14 Thus, interventions pro-
viding a clinical benefit are particularly warranted in
this group of patients, and are likely to have a large
impact on their health outcomes. Importantly, in our
study telemedicine not only showed an improvement in
non-fatal outcomes, but also was associated with
reduced healthcare costs, mostly due to a reduction in
hospitalization-related costs. Although a formal cost-
effectiveness evaluation was not conducted, our results
suggest thus that the improvements in clinical out-
comes with telemedicine would not mean increased
costs, but actually the opposite is true. With regards
to the feasibility of the intervention and the acceptabil-
ity of the technology used, previous studies conducted
in Catalonia have shown that CHF patients have a
high level of adherence to devices similar to those
used in our intervention, resulting in a very low pro-
portion of missed biometric daily transmissions.16,17
This supports the applicability of this technology in
clinical practice and beyond the setting of a rando-
mised controlled trial. Importantly, the same may not
apply to other types of technology, the heterogeneity of
which may explain the inconsistent results across pre-
vious studies evaluating different types of telemedicine
interventions in patients with CHF.20 If replicated in
larger cohorts, our findings suggest that telemedicine,
implemented using a technology similar to that used in
our study, should be considered for its incorporation as
part of standard CHF management programmes,
including those involving patients with LVEF 40%.
Study limitations
Our study has some limitations, mostly derived from
the single-centre nature of the trial and from the post-
hoc, subgroup nature of the present analysis. First,
because of the small sample size and the short follow-
up period, the number of deaths was relatively small,
and we were not sufficiently powered to identify differ-
ences between the study arms in terms of fatal end-
points. However, the incidence of all-cause death in
the usual care arm was twice that in the telemedicine
arm, pointing to a potential benefit of the intervention
also in terms of this endpoint. Larger studies are
needed to better understand the potential benefits of
telemedicine in terms of death in these patients.
Second, the small sample size also likely limited the
statistical power of the interaction tests. However, a
priori we have no reasons to expect telemedicine
being less effective in patients with HFmrEF (which
was the smallest study LVEF subgroup) than in
patients with HFpEF. Again, studies with larger
sample sizes are needed to better understand these
potential nuances, specifically to assess patients with
HFmrEF, a subgroup recently defined in the european
clinical guidelines.5
Third, the cost analyses conducted were explorato-
ry, the data available for the calculations was limited,
and information on the costs of the programme per
se was not available. Also, patient satisfaction and
other components relevant to patients and users
were not incorporated in the analysis. For all these
reasons, these findings should be considered
hypothesis-generating, and should be inter-
preted cautiously.
Fourth, the generalisability of the study findings to
other centres and healthcare environments is currently
unknown. Nevertheless, because in our area the usual
care arm involved gold-standard chronic care model
procedures,5,6,22 telemedicine compared to usual care
may have even greater benefits in areas in which
usual care is less developed.
Finally, the present results are consistent with those
already published by our group as part of the main
iCOR trial analysis.17 Nevertheless, the study included
a non-negligible number of patients with LVEF<40%,
and the relatively small sample size would have limited
the statistical power of any potential interaction tests.
Therefore, we decided to focus our attention specifi-
cally on the subgroup of patients with CHF and
LVEF40%, in whom interventions that are effective
in patients with LVEF<40% often fail to show a ben-
efit; and for whom the relevant scientific societies have
made calls for further research aimed at improving
their health outcomes.5
Conclusions
In this pilot, single-centre, randomised controlled trial
including CHF patients with LVEF40%, telemedi-
cine, as compared to usual care, was associated with
a lower risk of non-fatal acute HF events and of hos-
pitalization after six months of follow-up. If replicated
in larger cohorts, these results suggest that telemedicine
could represent a promising management approach to
improve the health outcomes of patients with CHF and
LVEF40%, a patient population that is expected to
grow in the coming decades, and for whom most phar-
macological interventions have so far failed to
show benefit.
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